Group 1: Stock Performance - Kangchen Pharmaceutical's stock price has been experiencing a decline, with a range between 39.54 yuan and 44.77 yuan, and a cumulative drop of 2.00% over five days [1] - On February 11, the stock fell by 1.66% with a trading volume of 99.41 million yuan and a net outflow of 9.56 million yuan [1] - The stock continued to decline on February 12, dropping 1.22% to close at 42.26 yuan, with a net outflow of 3.74 million yuan [1] Group 2: Company Developments - The company's R&D pipeline has gained market attention, particularly the KC1086 project, which is an innovative drug for advanced solid tumors, scheduled for a presentation in January 2026 [1] - The KC1036 project, aimed at treating esophageal squamous cell carcinoma, is progressing through Phase III clinical trials, although there have been no recent updates [1] - Kangchen Pharmaceutical conducted a detailed communication with 32 institutions regarding its R&D and operational status at the end of December 2025, but there have been no new records of institutional research in the past week [1] Group 3: Financial Performance - Kangchen Pharmaceutical expects a net profit of 145 million to 175 million yuan for the full year of 2025, representing a year-on-year growth of 243% to 315% [2] - The company's revenue for the first three quarters of 2025 reached 692 million yuan, a year-on-year increase of 7.10%, with a net profit attributable to the parent company of 128 million yuan, up 13.19% [2] - The gross profit margin for the company stands at 90.15%, driven by the performance of its main product "Sulingen" and growth in overseas business [2] Group 4: Market Insights - A report from Bohai Securities noted a 3.14% overall increase in the pharmaceutical and biotechnology sector in January 2026, with heightened attention on innovative drugs and CXO segments due to policy and industry conference influences [2] - However, the report did not provide a specific evaluation of Kangchen Pharmaceutical, and there have been no recent special ratings issued by institutions for the company [2]

二、回购股份的进展情况 证券代码：603590 证券简称：康辰药业 公告编号：临 2026-006 北京康辰药业股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/10/16，由董事会提议 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 10 | 10 | 月 | 15 | 日~2026 | 年 | 月 | 14 | 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | | 累计已回购股数 | 397,400股 | | | | | | | | | | 累计已 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2026-007 北京康辰药业股份有限公司 | 单位：万元 | | --- | | 序 | 受托方 | 产品名称 | 起始日 | 认购 | 产品期 | 赎回情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 名称 | | | 金额 | 限（天） | 本金金额 | 收益金额 | | | | "银河金 鼎"收益凭 证5317期- | 2025年 | | | | | | | 中国银 | | | | | | | | 1 | 河证券 | | 10月29 | 4,000 | 97 | 4,000 | 41.46 | | | 股份有 | 三元自动看 | 日 | | | | | | | 限公司 | 涨赎回（中 | | | | | | | | | 证A500） | | | | | | 特此公告。 北京康辰药业股份有限公司董事会 2026 年 2 月 5 日 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的 ...

Core Viewpoint - Kangchen Pharmaceutical (603590) is currently operating steadily and is adhering to regulatory requirements for information disclosure, with no undisclosed matters [1] Group 1: Company Operations - The progress of projects KC1086, KC1036, and ZY5301 is in line with expectations, with the clinical trial application for KC1086 having received FDA approval [1] - The marketing transformation has shifted from an alliance model to a self-operated dual-driven approach, significantly enhancing operational efficiency [1] Group 2: Financial Actions - The company is implementing a share buyback plan ranging from 50 million to 100 million yuan for employee stock ownership or equity incentives [1] Group 3: Business Growth - The overseas business of the company continues to grow steadily [1]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovative development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63%, with a total market value of 4.285 billion [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion [2] - Shutaishen rose by 3.94%, with a total market value of 1.3 billion [2] - Beilu Pharmaceutical increased by 3.49%, with a total market value of 584.3 million [2] - Tigermed rose by 3.37%, with a total market value of 56.3 billion [2]

Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovation and development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63% with a total market value of 42.85 billion and a year-to-date increase of 18.07% [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion and a year-to-date increase of 29.53% [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion and a year-to-date increase of 4.53% [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion and a year-to-date decrease of 2.89% [2] - Shutaishen and Beilu Pharmaceutical both saw increases of over 3%, with market values of 13 billion and 5.843 billion respectively [2]

Group 1 - The core viewpoint of the news is that Kangchen Pharmaceutical has seen a stock price increase of 5.08%, reaching 41.40 yuan per share, with a total market capitalization of 6.583 billion yuan [1] - Kangchen Pharmaceutical, established on September 3, 2003, focuses on innovative drug research and development, with its main business revenue composition being 70.77% from Suling, 29.15% from Salmon Calcitonin (Mikayxin), and 0.09% from other sources [1] - The trading volume for Kangchen Pharmaceutical was 1.45 billion yuan, with a turnover rate of 2.25% [1] Group 2 - Huabao Fund has a significant holding in Kangchen Pharmaceutical, with its Huabao New Vitality Mixed C Fund (003154) holding 14,100 shares, accounting for 1.09% of the fund's net value, making it the sixth-largest holding [2] - The Huabao New Vitality Mixed C Fund has a total scale of 51.4002 million yuan and has achieved a year-to-date return of 6.53% [2] - The fund manager, Yu Yinyou, has a tenure of 3 years and 216 days, with the best fund return during this period being 52.34% [2]

Core Viewpoint - As of January 20, a total of 142 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Fenglong Co., which has seen net buying for 15 consecutive trading days [1] - Other notable stocks with significant net buying days include Anhui Heli, *ST Guohua, Kangchen Pharmaceutical, Jiuding Investment, Shaanxi Coal and Electricity, Yili Co., Microelectrophysiology, and Gansu Expressway [1]

Core Viewpoint - As of January 19, a total of 144 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Fenglong Co., which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Anhui Heli, Shanghai Airport, Yong'an Forestry, *ST Guohua, Neway Group, Kangchen Pharmaceutical, Shentong Metro, and Qibin Group [1]